Amy Kamin - Endymed CEO of EndyMed USA
ENDY Stock | 330.00 2.00 0.60% |
CEO
Ms. Amy Kamin will no longer serve as Senior Vice PresidentBusiness DevelopmentNorth America at Endymed Medical Ltd, a Subsidiary of Endymed Ltd, effective June 20, 2018. She held this role from June 2010. Additionally, she will no longer serve as Chief Executive Officer at Endymed Medical Inc, a subsubsidiary of Endymed Ltd, effective June 20, 2018. She held this role since July 2013. She holds a Bachelors degree in Communications and Business from Chatham University, Pittsburgh, Pennsylvania.
Age | 56 |
Phone | 855 363 9633 |
Web | https://www.endymed.com |
Endymed Management Efficiency
The company has return on total asset (ROA) of 0.0385 % which means that it generated a profit of $0.0385 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2146 %, meaning that it generated $0.2146 on every $100 dollars invested by stockholders. Endymed's management efficiency ratios could be used to measure how well Endymed manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | CEO Age | ||
Gil Sharon | Bezeq Israeli Telecommunication | 51 | |
Yuval Bronstein | Azrieli Group | 47 | |
Doron Turgeman | B Communications | 49 | |
Leslie Thomas | Delek Group | 60 | |
David Mizrahi | Bezeq Israeli Telecommunication | 53 | |
Arnon Toren | Azrieli Group | 60 | |
Ron Eilon | Bezeq Israeli Telecommunication | 52 | |
Israel Keren | Azrieli Group | 76 | |
Ami Barlev | B Communications | 40 | |
Eyal Hankin | Azrieli Group | N/A | |
CecileEsther Eldan | Delek Group | 63 | |
Ran Guron | Bezeq Israeli Telecommunication | 55 | |
Shmuel Antzel | Delek Group | 57 | |
Eyal Lapidot | Delek Group | 52 | |
Stella Handler | Bezeq Israeli Telecommunication | 55 | |
Asaf Bartfeld | Delek Group | 66 | |
Mordechay Elmaliach | Bezeq Israeli Telecommunication | 57 | |
Eyal Chenkin | Azrieli Group | 47 | |
Nathan Haitchook | Alony Hetz Properties | 65 | |
Yosef Abu | Delek Group | 40 |
Management Performance
Return On Equity | 0.21 | |||
Return On Asset | 0.0385 |
Endymed Leadership Team
Elected by the shareholders, the Endymed's board of directors comprises two types of representatives: Endymed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Endymed. The board's role is to monitor Endymed's management team and ensure that shareholders' interests are well served. Endymed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Endymed's outside directors are responsible for providing unbiased perspectives on the board's policies.
Amir Schori, Vice President - Business Development | ||
Lee Gabay, Controller | ||
Ben Feldman, CFO | ||
Rami Aviram, Vice President - Finance | ||
Yossi CPA, Chief Officer | ||
Yoram Hert, CEO, Endymed Medical Ltd. | ||
Amiram Goldman, External Director | ||
Eran Naor, External Director, Independent Director | ||
Ronen Zadok, External Director | ||
Amy Kamin, CEO of EndyMed USA | ||
Elad Magal, CEO | ||
Yoram Harth, Founder, Director & Chief Medical Officer | ||
Yuan Yibing, Director | ||
Sima Weissman, VP RD | ||
Batsheva Elran, Director | ||
Sima Witman, Vice President - Research & Development | ||
Oren Maymon, Vice President - Operations | ||
Lior Cohen, Vice President of Sales | ||
Yosef BarOn, CEO | ||
Joseph Levtzler, Clinical VP | ||
Atzmon Shlush, Vice President - Operations | ||
Eran Ishay, Vice President - Research & Development | ||
Jan Jingran, Director | ||
Sharon Dovev, Director of Marketing | ||
Lior Vider, External Director | ||
Daniel Lishinsky, Vice President - Research & Development | ||
Idan Alfa, Finance Director | ||
Yocheved Dvir, Director | ||
Annie Jin, Director | ||
Lee Roth, Finance Director | ||
Zvika Lifschitz, Vice President - Finance | ||
Ofer Zvi, Director | ||
Bill Scott, Pres Inc | ||
Daniel Lischinsky, Founder and VP of RandD | ||
Moshe Cohen, Internal Auditor | ||
Frank Iannelli, Corporate Executive | ||
Amir Ganun, VP Marketing |
Endymed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Endymed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.21 | |||
Return On Asset | 0.0385 | |||
Profit Margin | 0.14 % | |||
Operating Margin | 0.06 % | |||
Current Valuation | 1.85 M | |||
Shares Outstanding | 13.76 M | |||
Shares Owned By Insiders | 58.11 % | |||
Price To Book | 0.70 X | |||
Price To Sales | 1.52 X | |||
Revenue | 21.78 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Endymed in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Endymed's short interest history, or implied volatility extrapolated from Endymed options trading.
Pair Trading with Endymed
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Endymed position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Endymed will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Endymed could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Endymed when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Endymed - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Endymed to buy it.
The correlation of Endymed is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Endymed moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Endymed moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Endymed can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Endymed. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Complementary Tools for Endymed Stock analysis
When running Endymed's price analysis, check to measure Endymed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Endymed is operating at the current time. Most of Endymed's value examination focuses on studying past and present price action to predict the probability of Endymed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Endymed's price. Additionally, you may evaluate how the addition of Endymed to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Fundamental Analysis View fundamental data based on most recent published financial statements | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Stocks Directory Find actively traded stocks across global markets |